Compare OBT & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OBT | MYGN |
|---|---|---|
| Founded | 1892 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 457.5M | 444.2M |
| IPO Year | 2021 | 1996 |
| Metric | OBT | MYGN |
|---|---|---|
| Price | $38.06 | $3.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $36.00 | $7.64 |
| AVG Volume (30 Days) | 38.2K | ★ 2.0M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.12% | N/A |
| EPS Growth | ★ 34.82 | N/A |
| EPS | ★ 1.87 | N/A |
| Revenue | N/A | ★ $771,400,000.00 |
| Revenue This Year | $14.27 | $6.86 |
| Revenue Next Year | $7.99 | $5.45 |
| P/E Ratio | $20.29 | ★ N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $23.25 | $2.74 |
| 52 Week High | $40.10 | $8.59 |
| Indicator | OBT | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 46.09 | 36.19 |
| Support Level | $35.90 | $2.79 |
| Resistance Level | $38.53 | $3.31 |
| Average True Range (ATR) | 0.81 | 0.17 |
| MACD | -0.13 | 0.08 |
| Stochastic Oscillator | 28.03 | 45.65 |
Orange County Bancorp Inc is a community bank holding company providing commercial and consumer banking services to individuals, small businesses, and local governments. It operates through two segments: Banking and Wealth Management. The Banking segment, the primary revenue driver, offers loans such as commercial real estate, construction, commercial & industrial, multifamily, and residential mortgages, along with services like cash management, escrow, deposits, ATMs, and digital banking. The Wealth Management segment provides investment management, trust services (trustee, administrator, custodian), and financial planning and advisory services to individuals and institutions.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.